Patient Advocacy Groups’ Favorability Towards Pharma Declines for Second Year Due to Drug Pricing Concerns.

Patient advocacy groups viewed the pharmaceutical industry with less favor for the second year in a row. The continued decline in reputation stems primarily from persisting worries regarding drug pricing. Specifically, the main driver of this downturn, as cited by multiple patient advocacy organizations, centers on concerns about the cost of medications. This issue has remained a prominent point of contention between patient groups and the pharmaceutical sector for the past two years.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Author

Mark Chiang